Achieve a HEALTHY summer body with the personal coaching app that helps you shed weight for good - see the before and after photo proof here
Losing weight takes some serious effort. The reality is that it's a struggle for many, whether they have issues with motivation or moderation. Wouldn't it be amazing to have someone who was constantly by your side to cheer you on?
With the Simple app, you quite literally always have a personal weight loss cheerleader in your pocket. The streamlined platform is designed to simplify the way you approach your goals, tailoring a plan that takes into account your personal challenges while helping you learn healthier habits over time.
Simple
It's time to take control of your weight loss goals! Simple is an app that helps you achieve them without the usual struggles. It's like having a motivating personal coach in your pocket!
The AI-powered platform is a joy to use, helping you make the right dietary choices, keep track of your goals, monitor your progress, and more.
You can contact your virtual coach 24/7 for real-time responses whenever you need them. The before and after photographs speak for themselves — Simple really works!
Get Started
Beautiful results: Users like Danielle have shared their incredible before and after photos revealing impressive weight loss thanks to the Simple app
That's often the key to seeing results that last. When you change the way you eat, everything changes for the better. Through Simple's AI-powered coaching, you'll discover how to make the best choices while understanding the 'whys' behind them.
Because that's important, too — and it's critical to making behavioral changes that have a chance of sticking so you can be healthy both now and in the future. You'll never feel guilted out of enjoying something you love, either. 'Everything in moderation' has always been an important adage, and it applies here, too.
Instead, Simple focuses on helping you achieve a more balanced lifestyle. No more restricting entire food groups you love or obsessively counting calories. Those are old, played out behaviors that are intrinsically more harmful than helpful.
What sets this app apart is that it genuinely prioritizes your wellbeing. Chat with your coach at any time and you'll receive straightforward, friendly, non-judgmental guidance during your journey. You'll only ever feel uplifted and motivated!
And it's backed by science, which is equally vital to your success. The entire goal is to help you lose the weight you want to lose and keep it off, which is why Simple encourages you to make small changes every day that gradually become a part of your everyday routine. That is what makes long-term success possible.
It's fun, too! Your onboarding process begins with a detailed questionnaire in which you'll provide information about your weight loss journey, current diet, and goals. It even provides you with a prediction of when you might expect to see results.
Habits for life: Simple is designed to simplify the often complicated world of weight loss, helping you make healthier choices that work
Plus, it's jam-packed with useful features — like NutriScanner, which gives you insight into nutrition from your favorite restaurant menus, intermittent fasting monitoring, nutrition scores for your meals, and a wealth of educational content. You can also pair the app with your smartwatch for seamless on-the-go coaching.
The results are absolutely astounding, with Simple users sharing dramatic photo evidence of their success. One couple lost an impressive 117 pounds together, and countless users have shed dramatic weight in as little as four weeks.
Why wait? If you're ready to achieve a truly healthy summer body that turns into the lifelong body of your dreams, get started with the Simple app today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
17 minutes ago
- Daily Mail
Millions more at risk of world's most infectious disease after patient visits second-largest Texas county
One of America's largest counties is on red alert after a resident was diagnosed with measles, potentially exposing millions more to the deadly disease. According to Dallas County Health and Human Services in Texas, the patient was a female in her mid-20s who was fully vaccinated but contagious from May 30 until June 7. She is currently a resident of Dallas County, which is the the second-most populous county in Texas and the eighth-most populous in the US, with a population of over 2.6 million people. The infected woman also traveled to the city of Plano, and she visited two businesses. On May 31 between the hours of 9am to noon the infected woman visited Lemma Coffee in the downtown area and the next day, on June 1, she went to the First Baptist church from 1pm to 5:30pm. Health officials said the woman has received care, and they are working to identify and notify individuals who may have been exposed. According to DCHHS, this is an ongoing investigation of an isolated case because the source of the woman's exposure to measles is not known. However, the new case comes as Texas is battling a measles outbreak that has infected nearly 800 people and killed two children. Dallas officials are warning anyone who fears they may have been exposed to contact their health provider and monitor for symptoms in what is the latest in a string of measles scares to rock America's major cities and travel hubs. This is the first case in Dallas County amid a major outbreak across Texas. At this time, 744 cases have been confirmed in the state since late January. Ninety-six of the patients have been hospitalized and there have been two fatalities in unvaccinated school-aged children who lived in the outbreak area. Overall, in the US there have been 1,168 confirmed measles cases reported by 34 states and at least three deaths. Measles is the world's most contagious disease - infecting nine out of 10 people exposed - but those who are fully vaccinated are protected in 97 percent of cases. The illness causes tiny white spots inside the mouth, flat red spots on the neck, torso, arms, legs, and feet, ear infections and a high fever. If severe, it can lead to life-threatening pneumonia. Children need two doses of the measles, mumps, rubella (MMR) vaccine: the first at age 12-15 months, and the second dose at age 4-6 years. Babies ages 6-11 months should get an early dose if traveling internationally. Adults should also check to see if they are immune to measles. About one to three in 1,000 people with measles dies of the illness. In an updated advisory, the CDC is warning that people can get infected with measles during travel or at crowded events, unless they are fully vaccinated or have had the disease. The notice reads: 'Travelers can catch measles in many travel settings, including travel hubs like airports and train stations, on public transportation like airplanes and trains, at tourist attractions, and at large, crowded events. 'Infected travelers can bring the disease back to their home communities where it can spread rapidly among people who are not immune.' The government agency recommends that all travelers be fully vaccinated against measles before traveling to an international destination. The last time measles was this rife in the US was in 2019, when there were 1,274 cases reported for the entire year. Measles was officially eradicated in the US in 2000 amid a successful vaccination campaign. At the time, the CDC described achieving measles elimination status in the US as a 'historic public health achievement'. However, a recent study found uptake of the vaccine among children declined in eight in 10 US counties last year, which is being signaled as the cause of the measles resurgence. Overall, vaccine rates fell three percent across the country. It means that 91 percent of children are vaccinated against measles, which is below the 95 percent needed to prevent the disease from spreading and causing deaths. The Johns Hopkins University researchers warned that if vaccination rates continue to fall, measles is likely to return and become a common infection among Americans.
The Independent
24 minutes ago
- The Independent
What do we really know about the long-term use of Ozempic and Mounjaro?
The headlines this week were as sensational as they were unsettling. ' Ozempic may stop the pill working properly,' this newspaper reported after the Medicines and Healthcare Products Regulatory Agency (MHRA) issued a warning: pill users should double up on contraception while using the jabs and avoid them altogether during pregnancy or breastfeeding. The British Menopause Society also added that women on HRT taking the drugs might fail to absorb progesterone pills, which could increase the risk of womb cancer. Meanwhile, other reports warned that the injections many are using for weight loss, like Wegovy and Mounjaro, might also carry a hidden risk of kidney cancer. And this month, the European Medicines Agency cautioned that semaglutide could double the risk of a rare sight-loss condition called non-arteritic anterior ischemic optic neuropathy (NAION). These headlines would be alarming even if the drugs were rarely used. But these so-called weight-loss jabs have become so popular that even their manufacturers didn't anticipate the demand. As of March 2025, market intelligence company IQVIA estimated that around 1.5 million people in the UK were using weight loss treatments. With limited NHS availability, roughly 80 per cent of these are purchased privately online and have made the pharma companies that make them some of the most valuable firms in Europe. But with no real long-term studies, do we really know how safe these drugs are? While they will have been thoroughly tested before hitting the market, have manufacturers really considered how people are using them? What do we really know about their long-term effects? Is this truly a medical breakthrough – or just another chapter in the troubled history of slimming pills? A crisis in need of solutions There's no denying that obesity is a public health emergency. Nearly three-quarters of people aged 45 to 75 in the UK are now overweight, up from just over half in 1993. Obesity is linked to conditions such as type 2 diabetes, heart disease, joint problems, infertility, and around 30 types of cancer. It's estimated to cost the NHS £6.5bn a year. Given this, the search for a safe, effective obesity drug has long been seen as medicine's holy grail. But past attempts have often ended in disaster, either due to limited results or serious safety issues. The troubled history of slimming drugs Weight loss drugs have historically come with significant risks. One of the earliest, 2,4-dinitrophenol, was initially used as an explosive in the First World War. It worked by increasing metabolism, causing the body to burn calories as heat. As hemlines rose in the 1920s, flappers flocked to it, but it turned out that the wrong dose could literally cook users from the inside. Horrific deaths meant the drug was banned in 1938. Later came amphetamine-based drugs, widely used in the Fifties and Sixties until their links to addiction and cardiovascular issues led to bans. More recently, sibutramine (Reductil) and rimonabant (Acomplia) were withdrawn after being linked to heart attacks, strokes, and psychiatric effects. By the time Acomplia was suspended in 2008, four trial participants had died by suicide. Enter: GLP-1 agonists. These new-generation drugs, which include semaglutide and tirzepatide, were the first to mimic our own natural appetite-regulating hormones. The first to hit the market was exenatide – a drug to treat type 2 diabetes – in 2005. Ozempic was then approved in 2017 and Mounjaro in 2023. Clinical trials showed unprecedented weight loss of up to 26 per cent of body weight in some cases, on par with bariatric surgery – and seemingly without the deadly side effects of their predecessors. So, why are these drugs different? 'Most previous drugs targeted the brain, which is where hunger lives,' explains Professor Giles Yeo, a molecular neuroendocrinologist at Cambridge University. 'But that led to serious side effects. These newer drugs are modified, longer-lasting versions of natural hormones – they're designed to go to the right brain regions naturally and for our body to respond to them in the same way they do to our own hormones.' Miracle or minefield? Despite their success, the rapid rise in use has triggered concern. Many users now access these jabs through private online clinics with minimal oversight. Some even acquire illegal 'compounded' medications from beauticians. Social media is flooded with user reviews, micro-dosing tips, and 'before-and-after' photos. But this week, a spokesperson for Novo Nordisk, which markets Ozempic and Wegovy, told the Daily Mail that practices like microdosing weren't recommended. 'The approved doses are the only dose strengths that have been studied and are licensed to use,' they warned. Similarly, the Royal Pharmaceutical Society has warned that without proper supervision, users face risks including dehydration, gallstones, malnutrition, and muscle loss. What do we know about long-term safety? Yeo is optimistic: 'Regulatory bodies like the FDA and the EMA are very rigorous. These drugs are approved globally, and they wouldn't be if they were deemed unsafe.' Professor Carel Le Roux, a metabolic medicine expert at Ulster University, adds that all approved drugs – not just weight loss drugs – must be studied for at least 52 weeks. This is because, he says, 'If we haven't seen major issues by a year, we're unlikely to. And this is based on the regulators' experience of tens of thousands of previous studies.' However, less obvious side effects often appear only after widespread use. Le Roux insists that the new findings that have dominated the headlines in the last few weeks are typical of standard 'post-market surveillance' by which pharma companies and regulators continue to collect data. 'Yes, things can emerge,' he says. 'But we've used this class of drugs for 20 years, mostly in people who were sicker than current users. The data is incredibly reassuring.' Le Roux also points out that in trials, participants on these medications had fewer serious adverse events than those on placebo. 'That's because obesity and diabetes are so harmful themselves. There comes a point when it's unethical not to license a drug that can make people healthier.' Untangling the risks Some risks are still being studied. The kidney cancer alert came from a study of 43,000 people on GLP-1 drugs versus 43,000 controls. There were 83 cases in the treatment group compared to 58 in the control group – a slight absolute increase and not necessarily a clear causal link. Conversely, other trials show strong kidney protection. The FLOW trial (2019–2023) followed over 3,500 patients and found a 24 per cent lower risk of kidney failure and a 50 per cent reduction in death from kidney disease among semaglutide users. The findings were so conclusive that the trial ended early in order to offer treatment to the placebo group. Le Roux remains confident: 'We've shown these drugs can reduce heart attacks by up to 25 per cent and cut the risk of developing diabetes in people at risk by 80-90 per cent. Yes, eye issues have emerged, but this particular condition is only seen in people with diabetes, and the risk is around 1 in 10,000.' Yeo also points out that in fact 'type 2 diabetes is the leading cause of blindness in adults'. So, what about the contraceptive and HRT concerns? Le Roux says vomiting, a known side effect of the drugs, is likely to be to blame rather than the drug blocking absorption per se. 'Anything swallowed will eventually be absorbed – unless it's thrown up.' To reduce nausea while on these drugs, he advises sticking with lower doses, even if that slows weight loss. If vomiting continues to be a problem, switching to non-oral forms of HRT, such as patches, or using condoms or a coil should eliminate the issue. Osteoporosis and other risks Others have expressed concerns about the effect of weight loss injections on muscles and bones. US singer Avery, who took Ozempic for a year, despite having an eating disorder, recently tearfully revealed she had been diagnosed with osteoporosis. She admitted that she did not get the drug from a doctor. So how common is her experience? A review published last year showed that between 15 and 40 per cent of weight loss with semaglutide could be lean tissue. Yeo says that it's something users should be aware of. 'Anyone losing weight by any means will always lose lean tissue – which includes water, muscle and bone – alongside fat.' However, he says there is no evidence this far that weight loss injections contribute independently to osteoporosis.' Yeo says the best way to mitigate bone loss is with exercise, which studies show can preserve muscle and bone density when taken with these drugs. A protein-rich diet also helps maintain muscle. Reviews have also shown that after weight loss, even though they lost lean tissue, people tended to end up with a higher proportion of lean mass compared to fat and that this muscle could be 'better quality' with stronger muscle fibres. However, in older people with fewer reserves, losing too much weight and muscle, which is harder to rebuild as we age, can be risky. The problem of dependency These drugs don't cure obesity – they manage it. Stop the injections and your appetite returns. One study found that patients regained two-thirds of the weight they had lost within a year of stopping treatment. This raises challenging questions. 'One of the most important questions we ask patients now is, 'Are you willing to take this medication for life?'' says Le Roux. And of course, this comes at a cost, whether it's private consumption (roughly £250 a month) or the NHS, which will have to consider covering lifetime prescriptions. And with the huge sums involved, how do we protect against black-market misuse? The next generation: hope or hype? Current drugs target only one or two appetite-regulating gut hormones. However, as Yeo explains, around 20 gut hormones influence satiety. Next-generation treatments may combine more hormones, allowing lower doses and potentially fewer side effects, such as vomiting. 'These could reduce digestive side effects to zero,' says Yeo. Some new generation weight loss medications are even being designed to protect muscle and bone mass by activating pathways that mimic the effects of exercise. Yeo says that future, cheap pill forms of the drugs may also prove the secret to lifelong maintenance. With the World Health Organisation announcing in May that it plans to endorse anti-obesity drugs for adult treatment, access may expand globally which could be a medical turning point But they're not for everybody... Few in medicine doubt that GLP-1 drugs mark a breakthrough. But they are not a one-size-fits-all solution. Around 15 per cent of patients don't respond. And there's growing concern that access remains limited to those who can afford private prescriptions, while NHS patients face restrictions. Many people take them without exercising or improving their diet, which is essential to preserve strong muscles and bones in the future. However, Yeo believes that change is on the way. 'In seven years, Ozempic's patent expires. I predict the cost will fall from £200 to maybe £10 a month. When that happens, the NHS will be able to provide it widely – with proper supervision. These powerful drugs are designed to be used for health reasons, not as a cosmetic tool. They are designed to help people with obesity. If they are taken by skinny people, that's when side effects rocket and the risk vs benefit ratio changes. We need to keep them out of the wrong hands.' Drugs like semaglutide offer a new weapon in the battle against obesity – a condition that has proven difficult to treat for decades and costs the NHS millions in comorbid conditions, which can range from type-2 diabetes, cancer, cardiovascular disease, osteoarthritis and even depression. But they aren't magic bullets. They come with risks, limitations, and hard decisions about long-term use. Appropriately used, with medical oversight and realistic expectations, they can be life-changing. But the real test isn't just in the weight lost this year – it's what happens over the next decade. We should welcome them, but with cautious optimism and our eyes wide open.
Daily Mail
an hour ago
- Daily Mail
BREAKING NEWS LA Rams star Alaric Jackson gets concerning medical diagnosis, throwing doubt onto his 2025 season
Rams offensive lineman Alaric Jackson is reportedly dealing with a concerning medical issue which has thrown his status for the 2025 season into question. Jackson, 26, has started 29 games over the last two seasons and was part of the Rams' Super Bowl-winning squad in the 2021 season. Now, however, the tackle is dealing with blood clots, according to NFL Network's Ian Rapoport. Jackson previously dealt with the same problem in 2022, as he missed nine games that year. More to follow #Rams OT Alaric Jackson, a key member of the O-line who just signed an extension, is dealing with blood clots once again, per The Insiders. Similar to what he had in 2022. While the belief is he'll play in 2025, there are still questions. That explains the DJ Humphries signing.
